Effect of Cherry Juice on Fat Oxidation and Cardio-metabolic Markers

December 16, 2016 updated by: Terun Desai, University of Hertfordshire

The Effect of Tart Cherry Juice Supplementation on Fat Oxidation, Body Composition and Cardio-Metabolic Markers With Cycling Exercise

The present study examined the effect of Montmorency tart cherry juice and FATMAX (intensity eliciting maximal fat oxidation) exercise on fat oxidation rates, body composition and blood-based cardio-metabolic markers. Participants received both Montmorency tart cherry juice and placebo in a random counterbalanced order for 20 days. Outcome variables were measured immediately pre- and post-supplementation and 10 days after the onset of supplementation. It was hypothesised that Montmorency tart cherry juice would increase fat oxidation during exercise, reduce body fat percentage and improve cardio-metabolic markers.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Aims: (1) Examine whether tart cherry juice supplementation with cycling exercise augments fat oxidation rate and therefore plays a role in weight management in healthy active human participants. (2) To extrapolate findings from this study to future biomedical health and disease research.

Methods: Random counterbalanced, within-group, double-blind study design. Participants were randomly allocated into consuming either cherry juice first or placebo. Eleven recreationally active male and female participants were recruited. Participants consumed 30ml Montmorency tart cherry juice concentrate mixed with 100ml water, twice daily for 20 days. Participants underwent a 14 day washout period between trials. All participants were instructed to keep to their habitual intake of polyphenols and anthocyanins. Twenty-four hours before each exercise testing session, participants consumed similar meals at the same times. Diet adherence was monitored through food diaries.

Participants attended each testing session following an overnight fast, with the testing being completed at the same time in the morning to avoid circadian variation. Preliminary testing was conducted to ascertain VO2max and individual FATMAX, 4 days before the one hour pre-supplementation exercise test. VO2max was re-assessed 4 days before the one hour post-supplementation exercise test to determine if any changes in training status affected results.

Testing will occur at baseline, 10 days after the onset of supplementation and after 20 days supplementation. Exercise protocol consisted of 60min cycling at pre-determined individual FATMAX. Continuous gas analysis and heart rate were monitored throughout. Substrate oxidation rates and energy expenditure were calculated using stoichiometric equations (Jeukendrup and Wallis, 2005). During each testing session blood pressure and body composition (impedance) measurements were taken at baseline and pre-exercise during all testing sessions. Resting metabolic rate (indirect calorimetry) was assessed at baseline and pre-exercise during all testing sessions.

Serum blood samples were obtained from participants at the following time points: baseline, pre-exercise and post-exercise for one hour submaximal exercise tests, in both trials. The following markers were analysed: Glucose, Lactate, Triglycerides, HDL, Total Cholesterol and Total Antioxidant Status.

Study Type

Interventional

Enrollment (Actual)

11

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 41 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 18-45
  • Male and Female
  • Non-smokers
  • Recreationally active (minimum 150 minutes physical activity per week)
  • Injury free at all times of testing.

Exclusion Criteria:

  • Aged <18 years old, >45 years old
  • Current or previous history of gastrointestinal, cardiovascular or renal disease
  • Current or previous history of injury that may be exacerbated with the exercise protocol used
  • Allergy to maltodextrin or specific fruit products (especially cherries) and those currently taking medication (such as steroids, NSAIDs, antibiotics) or currently using any nutritional supplement.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo

130ml serving twice daily (immediately before breakfast and dinner) for 20 days.

Placebo composition: Water (100ml), Cherry Squash Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml).
Other: Placebo
Experimental: Montmorency Tart Cherry Juice

130ml serving twice daily (immediately before breakfast and dinner) for 20 days.

MTCJ Composition: 100ml water and 30ml Montmorency tart cherry concentrate (Cherry Active, Sunbury, UK).
Dietary supplement: Montmorency Tart Cherry Juice

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in Fat Oxidation (grams/min)
Time Frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in Lipid Profile (Total Cholesterol, HDL, Triglycerides, LDL) (mmol/L)
Time Frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Change in Serum Glucose (mmol/L)
Time Frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Change in Body Fat Percentage (%)
Time Frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Change in Body Mass (kg)
Time Frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Change in Fat Mass (kg)
Time Frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Change in Fat Free Mass (kg)
Time Frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Change in Total Antioxidant Status (mmol/L)
Time Frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms
Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Hertfordshire

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2016

Primary Completion (Actual)

September 1, 2016

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

December 7, 2016

First Submitted That Met QC Criteria

December 16, 2016

First Posted (Estimate)

December 21, 2016

Study Record Updates

Last Update Posted (Estimate)

December 21, 2016

Last Update Submitted That Met QC Criteria

December 16, 2016

Last Verified

December 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LMS/PGT/UH/02336_

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe